(Total Views: 649)
Posted On: 02/02/2024 12:07:02 PM
Post# of 156317
LL vs GBM
>>Leronlimab solid tumour trial completed
CytoDyn’s leronlimab for CCR5+ locally advanced or metastatic solid tumours saw its PTSR increase in multiple cancer indications after its Phase II basket trial completed. The trial looked at 22 cancer types, and the largest PTSR changes occurred in glioblastoma multiforme (GBM), throat cancer, and bladder cancer. The PTSR leapt nine points to 32% in GBM, and four points to 37% in both throat and bladder cancer.>>
https://www.clinicaltrialsarena.com/features/...;cf-closed
>>Leronlimab solid tumour trial completed
CytoDyn’s leronlimab for CCR5+ locally advanced or metastatic solid tumours saw its PTSR increase in multiple cancer indications after its Phase II basket trial completed. The trial looked at 22 cancer types, and the largest PTSR changes occurred in glioblastoma multiforme (GBM), throat cancer, and bladder cancer. The PTSR leapt nine points to 32% in GBM, and four points to 37% in both throat and bladder cancer.>>
https://www.clinicaltrialsarena.com/features/...;cf-closed
(4)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
